◆ Contrarian Corpus
Corpus / Starboard Value → Qorvo, Inc.
activist 13D filing proxy fight
2025-04-14 · 24 pages

Qorvo, Inc. QRVO

N 1 Narrative
V 1 Visual
C 1 Craft
Unlock to download PDF Original source ↗

Primary demands

  • Elect Peter A. Feld to the Qorvo Board of Directors at the 2025 Annual Meeting
  • Add stockholder representation to the Board

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns. Orange cells are present in this deck; neutral cells are not.

Villain named CEO-quote contradiction Before / after framing Peer-gap chart Sum of parts Fraud exposé Break-up / spinoff Governance / board Management change Proxy fight Top visual craft Masterclass

Composition what's on the 24 slides

Visual + textual elements counted across every slide in this deck. Hover a box for what that element is; click to see every slide in the corpus that uses it.

0 charts 18 tables 0 callout boxes 0 quote blocks 0 screenshots 0 photos 0 bullet lists 0 diagrams

Slide gallery ·

All 24
No slide inventory yet

Pass-2 extraction may still be in progress for this deck.

Notes

Schedule 13D Amendment No. 2 filed 2025-04-14 disclosing Starboard's 8.9% stake in Qorvo and the April 14, 2025 nomination letter putting forward Peter A. Feld for election to the Board at the 2025 Annual Meeting. Pure SEC regulatory filing — no thesis prose, no slides, no valuation work; Item 4 narrative is limited to Feld's biography and a statement that Starboard expects continued discussions with the Issuer regarding Board composition. SCQA, thesis, and closing-ask fields are null because the document does not articulate a substantive investment case.

More from Starboard Value

Starboard Value Oct 01, 2024

Pfizer Inc. PFE

Pfizer squandered its $40bn COVID windfall on overpriced M&A while delivering almost none of the 15 promised blockbusters; the Board must hold management accountable.

N5 V4 C4
⌂ ◫ ” ⚑
↗ source
Starboard Value Oct 01, 2024

Pfizer Inc. PFE

Pfizer destroyed $20-60bn of value since 2019 despite a $40bn COVID windfall; Starboard wants the board to hold Bourla accountable for peer-median R&D/M&A returns.

N5 V4 C4
⌂ ◫ ” ⇌ ⚑
Starboard Value Mar 03, 2022

Huntsman Corporation HUN

Starboard is running a proxy fight for four Huntsman board seats, arguing a CEO-beholden board allowed 337% S&P underperformance and three missed Investor Day promises.

N5 V3 C3
⌂ ” ⇌ ⚑
Starboard Value Feb 28, 2022

Huntsman Corporation HUN

Huntsman, led by the founding family for its entire history, has missed three consecutive investor-day targets and lags peer EBITDA margins by ~900bps; Starboard's four nominees can unlock ~600bps of margin expansion.

N5 V4 C4
⌂ ” ⇌ ⚑
Starboard Value Mar 18, 2019

Bristol-Myers Squibb BMY

BMY is overpaying ~$30B for Celgene's risky pipeline, betting on 10 blockbusters in 8 years vs 3 in 15; shareholders should vote against and unlock 900bps of standalone margin upside.

N5 V3 C3
⌂ ◫ ” ⇌ ⚑
↗ source
Starboard Value Mar 01, 2019

Bristol-Myers Squibb BMY

BMY's $91B Celgene deal bets the company on a REVLIMID patent cliff and pipeline requiring 10 blockbusters in 8 years — shareholders should vote no and pursue a standalone Amgen-style transformation.

N5 V3 C3
⌂ ◫ ” ⇌ ⚑